Literature DB >> 9135944

Insulin and cognitive function in an elderly population. The Rotterdam Study.

R P Stolk1, M M Breteler, A Ott, H A Pols, S W Lamberts, D E Grobbee, A Hofman.   

Abstract

OBJECTIVE: To examine the association between insulin and cognitive function in the population-based Rotterdam Study. RESEARCH DESIGN AND METHODS: Serum insulin was measured 2 h after an oral glucose load, while global cognitive function was assessed by the Mini Mental State Examination in 5,510 subjects, aged 55 years and over.
RESULTS: An increase in postload insulin only in women was associated with a decrease in cognitive function (age-adjusted regression coefficient -0.10 per 50 mU/l insulin; 95% CI -0.16 to -0.04). The association between insulin resistance, assessed by the ratio of postload insulin over glucose, and cognitive function was not statistically significant. Further adjustment for the individual risk factors of serum glucose, BMI, HDL, systolic blood pressure, smoking, or use of estrogen did not change the results. The association was present in women with and without cardiovascular disease and present after excluding subjects with diabetes. Women with dementia, the extreme of cognitive dysfunction, had increased age-adjusted insulin levels (76.3 +/- 4.9 vs. 66.8 +/- 1.0 mU/l [means +/- SE], P = 0.06).
CONCLUSIONS: The results of this study suggest that increased serum insulin may be associated with decreased cognitive function and dementia in women. These findings are more compatible with a direct effect of insulin on the brain than with an effect through an increase in cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135944     DOI: 10.2337/diacare.20.5.792

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  55 in total

Review 1.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Cardiovascular risk factors and Alzheimer's disease.

Authors:  José A Luchsinger; Richard Mayeux
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

3.  Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance.

Authors:  H Bruehl; V Sweat; J Hassenstab; V Polyakov; A Convit
Journal:  J Clin Exp Neuropsychol       Date:  2010-06       Impact factor: 2.475

4.  Cognitive function and dental care utilization among community-dwelling older adults.

Authors:  Bei Wu; Brenda L Plassman; Jersey Liang; Liang Wei
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

Review 5.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

Review 6.  Estrogen: a master regulator of bioenergetic systems in the brain and body.

Authors:  Jamaica R Rettberg; Jia Yao; Roberta Diaz Brinton
Journal:  Front Neuroendocrinol       Date:  2013-08-29       Impact factor: 8.606

Review 7.  Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?

Authors:  Hutan Ashrafian; Leanne Harling; Ara Darzi; Thanos Athanasiou
Journal:  Metab Brain Dis       Date:  2013-05-08       Impact factor: 3.584

Review 8.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

9.  Regulation of adaptive behaviour during fasting by hypothalamic Foxa2.

Authors:  Jose P Silva; Ferdinand von Meyenn; Jessica Howell; Bernard Thorens; Christian Wolfrum; Markus Stoffel
Journal:  Nature       Date:  2009-12-03       Impact factor: 49.962

Review 10.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.